Search results for "Diabetes"
SGLT-2, GLP-1 effects on cardiovascular risk differ by age
Older patients had a greater relative reduction in major adverse cardiovascular events with sodium-glucose cotransporter-2 (SGLT-2) inhibitors versus glucagon-like peptide-1 (GLP-1) receptor agonists, a meta-analysis of more than 600 studies found.
https://immattersacp.org/weekly/archives/2025/02/04/2.htm
4 Feb 2025
Risk for CVD events elevated years before type 2 diabetes diagnosis
A Danish study found that patients with type 2 diabetes had a twofold higher prevalence of cardiovascular disease (CVD) events as long as three decades before their diagnosis versus matched comparators.
https://immattersacp.org/weekly/archives/2024/12/03/2.htm
3 Dec 2024
Intensive BP control improved outcomes in patients with type 2 diabetes, trial finds
A composite of nonfatal stroke, nonfatal myocardial infarction, treatment or hospitalization for heart failure, or death from cardiovascular causes was significantly lower among patients treated to a blood pressure (BP) target of less than 120 mm Hg versus one below 140 mm Hg.
https://immattersacp.org/weekly/archives/2024/11/26/4.htm
26 Nov 2024
ACP, Annals of Internal Medicine host forum on medications for type 2 diabetes
A full recording of "Pharmacologic Management of Type 2 Diabetes" is available for replay.
https://immattersacp.org/weekly/archives/2024/05/28/5.htm
28 May 2024
SGLT-2 inhibitors more effective than sulfonylureas, DPP-4 inhibitors as second-line therapy
Patients with type 2 diabetes who added a sodium-glucose cotransporter-2 (SGLT-2) inhibitor to metformin had greater reductions in HbA1c level and body mass at one year than those who added a sulfonylurea or dipeptidyl peptidase-4 (DPP-4) inhibitor, a U.K. study found.
https://immattersacp.org/weekly/archives/2024/05/14/4.htm
14 May 2024
Differentiating type 1 from type 2 diabetes in adults
Type 1 diabetes can be challenging to diagnose after childhood in part because the overt symptoms tend to be milder.
https://immattersacp.org/archives/2024/05/differentiating-type-1-from-type-2-diabetes-in-adults.htm
1 May 2024
Bariatric surgery improves long-term diabetes outcomes more than medication, lifestyle interventions
Patients who underwent bariatric surgery for type 2 diabetes had remission rates of 18.2% at seven years and 12.7% at 12 years, compared to 6.2% and 0%, respectively, in patients treated with medical and lifestyle interventions, a new review found.
https://immattersacp.org/weekly/archives/2024/03/05/1.htm
5 Mar 2024
Shifts in insulin use
Physicians' management of patients who take insulin for diabetes has been influenced by changes in pricing and access to technology.
https://immattersacp.org/archives/2024/02/shifts-in-insulin-use.htm
1 Feb 2024
Higher aspirin dose no more effective for CV prevention in high-risk patients with diabetes
A subgroup analysis of a randomized trial found that patients with diabetes and atherosclerotic cardiovascular disease had similar outcomes whether they took 81 mg or 325 mg of aspirin daily.
https://immattersacp.org/weekly/archives/2023/09/26/2.htm
26 Sep 2023
Almost 4 in 10 with type 1 diabetes were diagnosed in adulthood
Peak diagnosis age was approximately 15 years, and the median age of diagnosis was 24 years, but 37% of adults with type 1 diabetes reported having been diagnosed after age 30 years in a recent study.
https://immattersacp.org/weekly/archives/2023/09/26/1.htm
26 Sep 2023
SGLT-2 inhibitors reduced gout flares in patients with diabetes, gout
New users of sodium-glucose cotransporter-2 (SGLT-2) inhibitors had about half the risk of an ED visit or hospitalization for a gout flare as matched patients taking dipeptidyl peptidase-4 inhibitors, a cohort analysis found.
https://immattersacp.org/weekly/archives/2023/07/25/1.htm
25 Jul 2023
Large review compares benefits, harms of drugs to treat type 2 diabetes
High-certainty evidence indicated that sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists reduce all-cause death, while finerenone probably also reduced mortality based on moderate-certainty evidence.
https://immattersacp.org/weekly/archives/2023/04/18/4.htm
18 Apr 2023
Nocturnal hypoglycemia underdiagnosed in older patients on insulin for type 2 diabetes
An industry-funded study of patients ages 75 years and older who were taking insulin for type 2 diabetes found that almost two-thirds (65.2%) experienced nocturnal hypoglycemia during a 28-day study period.
https://immattersacp.org/weekly/archives/2023/04/04/1.htm
4 Apr 2023
Overweight, obesity poorly managed in type 1 diabetes
While U.S. adults with type 1 diabetes have rates of overweight and obesity virtually identical to those in the general adult population, only about 50% received lifestyle recommendations for weight management from clinicians or tried lifestyle modifications.
https://immattersacp.org/weekly/archives/2023/02/14/4.htm
14 Feb 2023
ADA updates diabetes standards of care for 2023
The American Diabetes Association (ADA) has changed its recommendations on hypertension cutoffs, use of statins, and treatment of patients with diabetes and chronic kidney disease, among other topics.
https://immattersacp.org/weekly/archives/2022/12/20/1.htm
20 Dec 2022
GLP-1 receptor agonists associated with thyroid cancer
Patients taking a glucagon-like peptide-1 (GLP-1) receptor agonist had about one and a half times the risk of developing thyroid cancer compared to similar controls, according to an observational French study.
https://immattersacp.org/weekly/archives/2022/11/22/2.htm
22 Nov 2022
Some newer diabetes drugs may help decrease risk of COPD exacerbation
A cohort study in the United Kingdom found that chronic obstructive pulmonary disease (COPD) exacerbations were less common in patients with type 2 diabetes and COPD taking glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors versus sulfonylureas.
https://immattersacp.org/weekly/archives/2022/11/08/4.htm
8 Nov 2022
ADA, EASD update guidance on managing hyperglycemia
An updated consensus statement from the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) addressed social drivers of health, lifestyle modifications, and new drug classes for type 2 diabetes.
https://immattersacp.org/weekly/archives/2022/10/04/1.htm
4 Oct 2022
Gestational diabetes associated with risks later in life, but lifestyle makes a difference, studies find
A review found increased risks of cardiovascular and cerebrovascular disease in women who had gestational diabetes, while another study showed that five markers of a healthy lifestyle were associated with a significant reduction in risk of developing type 2 diabetes after gestational diabetes.
https://immattersacp.org/weekly/archives/2022/09/27/4.htm
27 Sep 2022
Treatment pathways compared for diabetic peripheral neuropathy
Amitriptyline supplemented with pregabalin, pregabalin supplemented with amitriptyline, and duloxetine supplemented with pregabalin were similarly effective for controlling pain, a recent study found.
https://immattersacp.org/weekly/archives/2022/08/30/2.htm
30 Aug 2022